|
Tuesday, September 6, 2022 |
|
Sirnaomics受邀出席第三届富瑞亚洲论坛并作演讲 |
Sirnaomics Ltd.(“公司”,“Sirnaomics”,股份代号:2257.HK),是一家行业领先的专注于探索及开发RNAi疗法的生物制药公司。 more info >> |
|
Sirnaomics受邀出席第三屆富瑞亞洲論壇並作演講 |
Sirnaomics Ltd.(「公司」,「Sirnaomics」,股份代號:2257.HK),是一家行業領先的專注於探索及開發RNAi療法的生物製藥公司。 more info >> |
|
Sirnaomics to Present at 3rd Annual Jefferies Asia Forum |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today more info >> |
|
Monday, August 29, 2022 |
|
Sirnaomics核心产品STP705在治疗皮肤基底细胞癌II期临床试验组别中实现100%完全清除 |
Sirnaomics Ltd.(“公司”,“Sirnaomics”,股份代号:2257.HK),是一家行业领先的专注于探索及开发RNAi疗法的生物制药公司。 more info >> |
|
Sirnaomics核心產品STP705在治療皮膚基底細胞癌II期臨床試驗組別中實現100%完全清除 |
Sirnaomics Ltd.(「公司」,「Sirnaomics」,股份代號:2257.HK),是一家行業領先的專注於探索及開發RNAi療法的生物製藥公司。 more info >> |
|
Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the cohort receiving the 180ug dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response (CR) more info >> |
|
Friday, August 26, 2022 |
|
Sirnaomics推进基于GalAhead(TM)递送平台的RNAi疗法,用于治疗补体介导相关疾病 |
Sirnaomics Ltd.(“公司”,“Sirnaomics”,股份代号:2257.HK),是一家行业领先的专注于探索及开发RNAi疗法的生物制药公司。 more info >> |
|
Sirnaomics推進基於GalAhead(TM)遞送平台的RNAi療法,用於治療補體介導相關疾病 |
Sirnaomics Ltd.(「公司」,「Sirnaomics」,股份代號:2257.HK),是一家行業領先的專注於探索及開發RNAi療法的生物製藥公司。 more info >> |
|
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead(TM) RNAi delivery platform for developing novel therapeutic products focused on complement-related diseases. more info >> |
|
Monday, August 22, 2022 |
|
Sirnaomics获纳入恒生指数系列成份股 |
Sirnaomics Ltd.(“Sirnaomics”或“公司”,股份代号:2257.HK),一家行业领先的专注于探索及开发RNAi疗法的生物制药公司,宣布公司将获恒生指数有限公司纳入八个指数成份股 more info >> |
|
|
|